Executive Summary: Key Legal and Evidentiary Issues

• Ontario plaintiffs sought certification of a national product-liability class action alleging that Johnson & Johnson’s talc-based baby powder, when used perineally, increased the risk of epithelial ovarian cancer and was sold without adequate warnings.
• Johnson & Johnson argued the Ontario action should be stayed as an abuse of process because of overlapping certified class proceedings in British Columbia and an authorized action in Québec, raising issues of comity, duplication, and judicial economy.
• The court compared the Ontario and B.C. actions and found material differences in class scope, causes of action (including Competition Act and broader consumer protection claims), and available remedies that made the Ontario action more expansive.
• Expert epidemiological evidence on general causation and the finite number of epithelial ovarian cancer sub-types was accepted as providing a workable basis for common issues, distinguishing this case from other product cases where individual causation dominated.
• The judge held that, despite overlapping proceedings and many individual actions, an Ontario class proceeding remained a fair, efficient and preferable procedure, particularly for access to justice and behaviour-modification objectives.
• Plaintiffs’ late attempt to add a new New Brunswick statutory cause of action under the Consumer Product Warranty and Liability Act was refused as an improper “litigation in installments,” and no damages or costs amounts were fixed in this decision.

Background and parallel proceedings

This case arises from allegations that Johnson & Johnson marketed talc-based baby powder as a non-essential cosmetic product without adequate warnings about an alleged increased risk of epithelial ovarian cancer (EOC) when the product was used in the perineal area over a prolonged period. The representative plaintiffs in Ontario allege negligence, breaches of provincial consumer protection legislation, and violations of the Competition Act, seeking damages, punitive damages, and restitutionary relief against Johnson & Johnson Inc., Johnson & Johnson, and Johnson & Johnson Consumer Companies, Inc. The litigation did not begin in a vacuum. Similar or overlapping class proceedings were commenced in British Columbia and Québec, and a further action in Alberta was started but appears to have remained dormant. The B.C. action, later styled Ennis v. Johnson & Johnson, was certified on a Canada-wide basis, subject to important limitations on class definition and causes of action. The Québec action was authorized and upheld on appeal in 2018 but, on the record before the Ontario court, had not materially progressed in recent years. The Ontario proceeding, filed in 2016, moved more slowly than B.C. for a period, in part because all of the Canadian talc actions were affected by Johnson & Johnson’s unsuccessful US bankruptcy strategy between 2021 and 2023, which delayed progress while the defendants attempted to channel North American talc claims through restructuring proceedings.

Earlier Ontario certification ruling and outstanding issues

In June 2025, the Ontario Superior Court (the “June Reasons”) held that the plaintiffs had satisfied all but one of the statutory criteria for certification under s. 5(1) of the Class Proceedings Act, 1992 (CPA) as then applicable. The court found there were causes of action, identifiable classes, common issues, and a suitable representative plaintiff, and it rejected a stay based on delay. However, the judge adjourned two core questions: whether the Ontario proceeding should be stayed as an abuse of process in light of the overlapping B.C. and Québec actions, and whether an Ontario class action was the preferable procedure under s. 5(1)(d) of the CPA. The court did so because Johnson & Johnson had appealed the B.C. certification decision, and the Ontario judge wanted the appellate outcome in B.C. before finally ruling on duplication, comity, and preferability. The B.C. appeal was never argued. Instead, Johnson & Johnson abandoned it in late 2025, leaving the Ennis certification order in place. That development triggered the resumption of the Ontario stay and preferability issues, which were argued on supplementary submissions in December 2025, leading to the March 2026 reasons now under discussion.

Scope and differences between the Ontario and B.C. class actions

A central evidentiary and legal issue in this decision was the comparative scope of the Ontario and British Columbia actions. Johnson & Johnson and the intervening B.C./Québec plaintiffs pressed the court to view the Ontario proceeding as duplicative and unnecessary, emphasizing the risks of inconsistent findings, waste of resources, and unfairness to defendants faced with multiple overlapping national claims. The Ontario plaintiffs countered that their proceeding was not a mere “carbon copy” of Ennis. They filed a detailed comparison chart showing how the Ontario class definition, causes of action, and remedial landscape differed materially from the B.C. certification order. Substantively, the Ontario class is broader. Unlike B.C., Ontario does not exclude particular EOC sub-types at the certification stage, treats subtype questions as premature, and allows all EOC histologies to remain within the class subject to expert evidence at trial. Ontario also does not require an EOC diagnosis to be a class member; purchasers and perineal users of baby powder without a diagnosis are included to preserve consumer protection and Competition Act claims. By contrast, the B.C. class requires a diagnosis of EOC and imposes a minimum of ten years of daily use, along with temporal cut-offs for diagnosis, excluding, for example, persons diagnosed after a certain date. Ontario also includes Québec residents and seeks relief under Québec’s consumer statute for them, whereas Québec’s own authorized class action has shown no movement for more than five years.

Expanded causes of action and remedies in Ontario

The Ontario decision highlighted that the causes of action certified there go beyond those permitted in B.C. Whereas the B.C. court certified failure-to-warn negligence and certain consumer protection statutes tied to diagnosed EOC, it struck negligent design, negligent manufacturing, and Competition Act claims from the BC class proceeding. In Ontario, by contrast, negligent testing and design, negligent manufacturing, and Competition Act claims were all certified as common issues. Ontario’s consumer protection claims also encompass more provinces (including, for example, Québec and Newfoundland and Labrador) and are not limited to class members with a cancer diagnosis. The Ontario action further preserves access to restitutionary and disgorgement remedies—explicitly rejected in the B.C. certification reasons—alongside aggregate damages and punitive damages for both negligent and statutory wrongs. These differences matter at the preferability and stay stages because they expand the potential class size and the scope of potential recovery in Ontario. The judge treated the broader Ontario framework as a genuine access-to-justice enhancement, not merely a lawyer-driven attempt to duplicate proceedings.

Abuse of process and the motion to stay

On the stay motion, the court canvassed case law from across Canada on overlapping class actions, including decisions where duplicative, dormant, or “carbon copy” claims were stayed as abuses of process, and others (such as Kirsh and SNC-Lavalin) where parallel actions were allowed to proceed. The judge accepted that multiple proceedings can threaten judicial economy, cause confusion for class members, and create comity concerns, but stressed there is no presumption in favour of staying overlapping class actions, nor a “first to file” or “first to certify” rule. Instead, the court examined the context: both Ontario and B.C. actions were supported by serious records, expert evidence, and significant investment of resources; both had been prosecuted in good faith; and delays were partly driven by the defendants’ own restructuring strategy in the United States. The Ontario action was not a placeholder or bargaining chip. Crucially, the court was persuaded that the Ontario class action’s broader class and causes of action translated into potentially broader recovery and greater access to justice for Canadian consumers. That broader reach, combined with the finite and structured nature of the common causation issues, led the judge to conclude that allowing Ontario to proceed would not undermine the administration of justice or offend principles of comity. Mechanisms such as case management, cross-provincial communication, and future coordination (including possible decertification or modification of class parameters, if needed) were identified as tools to manage any duplication. The motion to stay the Ontario proceeding as an abuse of process was therefore dismissed.

Preferability of the Ontario class proceeding

Turning to the outstanding certification criterion under s. 5(1)(d) of the CPA—preferability—the court evaluated whether a class proceeding was a fair, efficient, and manageable way to resolve the common issues and whether it was preferable to other available procedures, in light of the goals of judicial economy, access to justice, and behaviour modification. Product liability claims of this type, the judge held, are “eminently suitable” for common resolution of general causation, failure-to-warn, and punitive-damages issues because they focus on the defendants’ conduct across a large group of users rather than the intricacies of any one person’s medical history. Johnson & Johnson argued that differences in epidemiological risk across ovarian cancer sub-types and individual risk profiles would swamp any common issues and reduce the class action to a loose aggregation of individual trials, akin to the scenario in the Price v. H. Lundbeck A/S case where certification was refused. The Ontario court rejected that analogy. Here, the evidence showed a finite set of EOC sub-types and a reasonably structured scientific debate about their association with perineal talc use, including evidence of a statistically significant increased risk for the most common lethal sub-type, all of which could be addressed through common expert evidence at a general causation trial. While individual causation and damages would remain for later stages, the common issues were robust enough to materially advance the litigation.

Individual actions and alternatives to a class proceeding

The defendants also relied on the existence of many individual actions—dozens in Ontario and British Columbia, and a handful in Alberta—where plaintiffs alleged talc-related ovarian cancer. Some of these had progressed to the point of exchanges of extensive medical records, expert reports, and even scheduling of discoveries and potential trial steps. Johnson & Johnson argued that these individual proceedings, together with the B.C. and Québec class actions, provided a sufficient alternative landscape, making an Ontario class action unnecessary and non-preferable. The judge disagreed. The need for each individual plaintiff to marshal complex expert causation evidence on their own, in the absence of an overarching common issues determination, was seen as antithetical to judicial economy and to access to justice, particularly in a mass-tort context involving a consumer cosmetic product with no therapeutic benefit. The court noted that, even on the defendants’ own submissions in earlier filings, efficiencies could be found through coordinated discovery, common productions, and joint examinations of defence witnesses across the various actions. In that light, refusing to certify Ontario for the sake of “cleanliness” in the litigation map would, in practice, limit practical recovery options for a broader class of purchasers and users and diminish the behaviour-modification function of the law.

Multi-jurisdictional coordination and statutory guidance

The decision also engaged with Ontario’s multi-jurisdictional class-action provisions, specifically s. 5(6) and (7) of the CPA, which require the court to consider whether it would be preferable for some or all claims or common issues to be resolved in another jurisdiction where a parallel proceeding has been commenced. The statutory objectives—giving due consideration to the interests of parties in all affected jurisdictions, serving the ends of justice, avoiding irreconcilable judgments where possible, and promoting judicial economy—were applied to the talc litigation’s cross-provincial structure. The court recognized the theoretical risk of inconsistent outcomes if, for example, one province ultimately found no liability while another did. However, it emphasized that the certification outcomes already diverged because different evidentiary records and submissions were put before the respective courts. These are not strictly “the same set of facts” producing inconsistent rulings; rather, they are related but distinct frameworks shaped by the particular evidence and legal theories advanced. The judge highlighted that, in the absence of a national legislative framework like that existing in the United States, Canadian courts must rely on comity, coordination, and flexible case management to navigate such overlap, not on rigid first-in-time rules that might sacrifice access to justice for technical tidiness.

Refusal of the New Brunswick statutory amendment

A narrower, but still important, aspect of the ruling concerned the plaintiffs’ attempt to enlarge the statutory foundation of the Ontario claim late in the certification process. After the June Reasons had invited “limited” further submissions on the defendants’ argument that certain New Brunswick and Yukon consumer protection statutes did not prohibit deceptive practices, the plaintiffs acknowledged that the New Brunswick Consumer Protection Act cited by the defence was not yet in force. They then sought leave to amend their pleading to add a new cause of action under the older New Brunswick Consumer Product Warranty and Liability Act (CPWL Act). Johnson & Johnson opposed the amendment, arguing it would reopen common-issues debates already addressed, introduce new privity and overlap questions with negligence, and effectively turn certification into a rolling exercise. The court agreed. It characterised the attempt as an example of impermissible “litigation in installments” or “litigation by slices,” where parties hold back arguments or legal theories to deploy later rather than advancing their full case in a timely way. Given the age of the action (commenced in 2016), the narrow scope of the court’s invitation for supplementary submissions, and the sufficiency of existing negligence and consumer protection claims to support certification, the judge refused leave to amend to add the CPWL Act claim.

Overall outcome and status of monetary relief

In the result, the court dismissed Johnson & Johnson’s motion to stay the Ontario proceeding as an abuse of process and rejected its argument that the existence of the B.C. and Québec class actions and numerous individual actions rendered the Ontario class action non-preferable. The motion for leave to amend to add a New Brunswick CPWL Act statutory cause of action was refused. The court then confirmed that, together with its earlier June Reasons, all criteria for certification under the CPA were met, and the talc baby-powder case would proceed in Ontario as a certified class proceeding with the class definition and common issues previously settled. At this stage, however, the court did not decide liability or quantify any damages or costs; it simply established the procedural framework within which future merits determinations will occur. For purposes of this decision, the substantially successful party is the plaintiff class, which achieved certification and defeated the stay, while the defendants succeeded only on the narrow amendment issue. No damages, compensation, or quantified costs were ordered in favour of any party in this ruling, and any future costs of the motions were left either to agreement or to short written submissions to be decided later, so the total monetary award or costs in favour of the successful party cannot be determined from this decision.